by Thomas Rønn | Jul 1, 2022 | Press Releases
Attgeno develops novel nitric oxide donators which are selective for the pulmonary circulation, making them safe and without systemic side-effects.Attgeno has developed Supernitro, a first in class therapy for the specific delivery of Nitric Oxide (NO) in the lung...
by Thomas Rønn | Jun 3, 2022 | Press Releases
Eir ventures has established itself as a well-respected professional investor in the Nordic life science ecosystem and will continue to build the organization and network to key stakeholders in the region. In accordance with this aim, Eir Ventures is expanding the...
by Thomas Rønn | May 21, 2022 | Press Releases
Cinclus Pharma is a Swedish biopharmaceutical company that is developing novel small molecules for the treatment of gastroesophageal reflux disease (GERD). The lead candidate, linaprazan glurate, belongs to a novel class of drugs, so called Potassium-Competitive Acid...
by Thomas Rønn | Mar 10, 2022 | Press Releases
Scenic Biotech is a pioneer in the discovery of genetic modifiers to enable the development of disease modifying therapeutics for rare genetic disorders Read the full Press Release here
by Thomas Rønn | Feb 23, 2022 | Press Releases
Eir Ventures today announced the completion of an investment in Strike Pharma, a Swedish biotechnology company that is developing personalized precision medicines within the immune-oncology space. The technology offers the potential to not only increase therapeutic...
by Thomas Rønn | Jan 26, 2022 | Press Releases
University of Copenhagen and Eir Ventures has agreed a unique co-investment agreement where the University allocates DKK 15 million to co-investments with Eir Ventures. Read the full Press Release here
by Thomas Rønn | Jan 5, 2022 | Press Releases
Pok Yeung Lee and Jorge Pérez Hermilla, two MMSc students from the Bioentrepreneurship program anchored at Karolinska Institutet and Royal Institute of Technology, will join the Eir Ventures Stockholm team in January 2022. Pok Yeung has previous investment analyst and...
by Thomas Rønn | Dec 20, 2021 | Press Releases
Dec 20, 2021 Eir Ventures welcomes Tobias Horneman-Thielcke as senior Principal in the Eir Ventures Team. Tobias is a physician and holds a BA in Law. Tobias started his career working as a physician in the clinic and later transferred to the pharmaceutical industry,...
by Thomas Rønn | Dec 9, 2021 | Press Releases
Eir Ventures Partners AB (“Eir Ventures” or “the Fund”), a Nordic Life Science Venture Capital manager, today announced the final close of its fund Eir Ventures I AB of EUR 122.3 million. Read the full Press Release here
Recent Comments